Diana Q Ho, MD
Dermatology · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Offices
- 2
Offices
2 locations · Permanente Medical Group Inc · 10,928 clinicians in this group
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ho’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence A74281 · Current
Licensed to practise in California · since 2001 · expires 2027-03-31 · Tufts University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$6,335
Pharmacies billed $6,335 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (13 of 180) in 2024. A higher opioid share than 9 in 10 peers; the typical dermatology clinician is at 0%.
155 generic and 25 brand-name prescriptions · $6,335 in drug cost · 38 antibiotic prescriptions to 32 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Calcipotriene | 21 | $1,610 | $77 |
| Fluorouracil | 20 | $730 | $37 |
| Cephalexin | 28 | $288 | $10 |
| Triamcinolone Acetonide | 13 | $146 | $11 |
| Hydrocodone-Acetaminophen | 13 | $113 | $9 |
Year by year
| 2024 | 180 | 84 | 7% (13) | 14% | $6,335 |
| 2023 | 134 | 62 | None | None | $6,725 |
| 2022 | 141 | 53 | None | 14% | $30,888 |
| 2021 | 119 | 66 | None | 9% | $6,148 |
| 2020 | 111 | 66 | None | 11% | $5,307 |
| 2019 | 167 | 97 | None | 12% | $8,032 |
| 2018 | 209 | 119 | 11% (22) | None | $11,585 |
| 2017 | 166 | 99 | 8% (14) | None | $8,004 |
| 2016 | 230 | 106 | 5% (12) | 22% | $18,432 |
| 2015 | 212 | 130 | 7% (15) | 13% | $17,231 |
| 2014 | 233 | 110 | 8% (19) | None | $17,479 |
| 2013 | 298 | 156 | 5% (16) | None | $25,000 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Cephalexin | 30 | $311 | $10 |
| Minoxidil | 12 | $112 | $9 |
2022: 1 drug
| Hydrocortisone | 12 | $357 | $30 |
2021: 3 drugs
| Fluorouracil | 22 | $1,381 | $63 |
| Cephalexin | 29 | $298 | $10 |
| Triamcinolone Acetonide | 11 | $139 | $13 |
2020: 2 drugs
| Fluorouracil | 16 | $1,074 | $67 |
| Cephalexin | 24 | $224 | $9 |
2019: 1 drug
| Cephalexin | 43 | $417 | $10 |
2018: 5 drugs
| Fluorouracil | 24 | $3,253 | $136 |
| Retin-A | 22 | $933 | $42 |
| Cephalexin | 50 | $533 | $11 |
| Triamcinolone Acetonide | 19 | $436 | $23 |
| Hydrocodone-Acetaminophen | 19 | $142 | $7 |
2017: 4 drugs
| Fluorouracil | 11 | $1,500 | $136 |
| Retin-A | 24 | $892 | $37 |
| Cephalexin | 41 | $452 | $11 |
| Hydrocodone-Acetaminophen | 13 | $133 | $10 |
2016: 7 drugs
| Azelex | 11 | $3,487 | $317 |
| Fluorouracil | 14 | $2,307 | $165 |
| Imiquimod | 13 | $1,649 | $127 |
| Retin-A | 22 | $738 | $34 |
| Cephalexin | 48 | $632 | $13 |
| Triamcinolone Acetonide | 16 | $332 | $21 |
| Hydrocodone-Acetaminophen | 12 | $293 | $24 |
2015: 4 drugs
| Imiquimod | 20 | $4,188 | $209 |
| Azelex | 11 | $3,118 | $283 |
| Cephalexin | 74 | $946 | $13 |
| Hydrocodone-Acetaminophen | 15 | $379 | $25 |
2014: 7 drugs
| Imiquimod | 15 | $4,351 | $290 |
| Clobetasol Propionate | 13 | $2,267 | $174 |
| Fluocinolone Acetonide | 11 | $1,801 | $164 |
| Cephalexin | 56 | $683 | $12 |
| Hydrocortisone | 13 | $382 | $29 |
| Hydrocodone-Acetaminophen | 18 | $256 | $14 |
| Triamcinolone Acetonide | 11 | $245 | $22 |
2013: 6 drugs
| Imiquimod | 24 | $9,588 | $399 |
| Fluorouracil | 20 | $5,123 | $256 |
| Cephalexin | 79 | $1,101 | $14 |
| Hydrocortisone | 15 | $523 | $35 |
| Ibuprofen | 11 | $160 | $15 |
| Hydrocodone-Acetaminophen | 16 | $151 | $9 |
Money from drug and device companies
$184 in 2025
| 2025 | 2 | 3 | None | $184 |
| 2019 | 1 | 1 | None | $46 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 3 published payments
| Pfizer | Meals · 2025-10-25 | Litfulo | $58 |
| Incyte | Meals · 2025-10-24 | Opzelura | $65 |
| Pfizer | Meals · 2025-10-23 | Cibinqo | $62 |
See earlier years (2019)
2019: $46
| E.R. Squibb & Sons L.L.C. | Nulojix | $46 | 1 payment
|
Professional record
- NPI
- 1891845608
- Licence
- CA A74281California A74281: Current · expires 2027-03-31
- Trained
- Tufts University School of Medicine, 1999
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 1800 Harrison St Fl 7, Oakland, CA, 94612
- NPI first listed
- 2007-01-12
- NPI last updated
- 2021-12-08
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.